Why the study?
Cardiovascular disease is the leading nonmalignancy cause of death in radiation-treated cancer survivors, but long-term cardiac effects of contemporary techniques remain unclear and management is complex.
What are the epidemiology, pathophysiology, and management strategies for cardiac complications following thoracic irradiation in cancer survivors?
Population
Cancer survivors treated with thoracic radiation therapy
Design
Review
Authors
Loading...
May warrant long-term cardiac surveillance after thoracic radiation; leaves open optimal prevention and screening strategies.
What are the epidemiology, pathophysiology, and management strategies for cardiac complications following thoracic irradiation in cancer survivors?
Cardiovascular disease is the leading nonmalignancy cause of death in thoracic radiation-treated cancer survivors, highlighting the need for awareness, early identification, and long-term follow-up.
Jaworski et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: